Document:

Exhibit 10.2

Exhibit 10.2

EXECUTION COPY

Henry Schein, Inc.

135 Duryea Road

Melville, NY 11747

February 16, 2010

Biolase Technology, Inc.

4 Cromwell

Irvine, CA 92618

	 	 	 
	Attention:

	 	David M. Mulder
	 

	 	Chief Executive Officer

Dear Mr. Mulder,

This letter agreement shall serve to amend that certain License and Distribution Agreement by
and between Henry Schein, Inc. (“HSI”) and Biolase Technology, Inc. (“Biolase”), dated as of August
8, 2006, as amended (the “Agreement”). Capitalized terms used herein but not defined herein have
the meanings set forth in the Agreement.

	 	1)	 	In full satisfaction of any purchase or related obligations in the Agreement, including
the letter agreement dated February 27, 2009 (the “Letter Agreement”), HSI shall make
advance payments of $5.8 million in respect of Biolase products by transfer of immediately
available cash funds, as follows: ****. Payments **** shall be made ****. HSI may issue
purchase orders for Biolase products or services **** in respect of such advance payments,
and notwithstanding the expiry of the term of the Agreement, Biolase will provide HSI with
**** consistent with the spirit of the Agreement. For the avoidance of doubt, HSI may sell
and distribute at any time any Biolase inventory purchased prior to or after the date
hereof. To facilitate Biolase’s planning, HSI will provide, within ten (10) days of the
date hereof, a **** of its ****; provided however, the absence of such
estimate, or estimates that reflect purchase levels that are less than the **** shall not
under any circumstances relieve obligation of HSI to make the advance payments ****, and in
the ****.

	 	2)	 	To secure the $5.8 million advance payment, Biolase will agree to enter into a security
agreement to be provided by HSI following the execution of this letter agreement containing
terms and conditions consistent with those of the security agreement entered into in
connection with the Letter Agreement (except as modified by this paragraph), and will
consent to the filing of the related UCC or UCCs to effect a security interest for the
benefit of HSI in Biolase’s inventory; provided that HSI shall agree to release such
security upon receipt of the products deliverable in respect of such $5.8 million payment.

	 	3)	 	Upon written notice from HSI to Biolase, **** will be upgraded by Biolase, by HSI’s
pre-payment to Biolase of ****, in the event Biolase introduces **** for products of the
type HSI maintains in inventory or purchases pursuant to this Letter Agreement.

	 	 	 
	****	 	Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

 

EXECUTION COPY

	 	4)	 	Pricing solely in respect of HSI’s purchases hereunder (totaling $5.8 million in
purchases) will be at ****, and ****.

This letter agreement amends certain terms and conditions of the Agreement. All other terms
and conditions of the Agreement that are not modified by this letter agreement are hereby ratified
and confirmed in all respects, and shall remain in full force and effect. Should there be any
conflict between the terms and conditions contained in this letter agreement and the Agreement, the
terms and conditions of this letter agreement shall govern and control.

This letter agreement shall be governed by, and construed and enforced in accordance with the
laws of the State of California, without regard to conflict of laws principles.

Please acknowledge your agreement to the foregoing terms and conditions by executing this
letter agreement.

	 	 	 	 	 
	Very truly yours,

HENRY SCHEIN, INC.

 	 	 
	By:  	/s/ Brian S. Watson
 	 	 
	 	Name:  	Brian S. Watson 	 	 
	 	Title:  	Vice President 	 	 
	 
	ACCEPTED AND AGREED:

BIOLASE TECHNOLOGY, INC.

 	 	 
	By:  	/s/ David M. Mulder
 	 	 
	 	Name:  	David M. Mulder 	 	 
	 	Title:  	Chief Executive Officer 	 	 

	 	 	 
	****	 	Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Exhibit 10.3

Exhibit 10.3

Henry Schein, Inc.

135 Duryea Road

Melville, New York 11747

February 24, 2010

Biolase Technology, Inc.

4 Cromwell

Irvine, CA 92618

	 	 	 	 	 
	Attention:

	 	David M. Mulder	 	 
	 

	 	Chief Executive Officer
	 	 

Dear Mr. Mulder,

This letter agreement shall serve to amend that certain License and Distribution Agreement by
and between Henry Schein, Inc. (“HSI”) and Biolase Technology, Inc. (“Biolase”), dated as of August
8, 2006, as amended (the “Agreement”). Capitalized terms used herein but not defined herein have
the meanings set forth in the Agreement.

As of the date set forth above, the parties hereby agree as follows:

Section 6 of the letter agreement, dated February 27, 2009 amending the Agreement, is
hereby amended such that HSI may provide written notice of its intent to extend the
Agreement for the first additional one year term at any time on or prior to 5:00 p.m.
E.S.T., Wednesday, March 3, 2010.

This letter agreement amends certain terms and conditions of the Agreement. All other terms
and conditions of the Agreement that are not modified by this letter agreement are hereby ratified
and confirmed in all respects, and shall remain in full force and effect. Should there be any
conflict between the terms and conditions contained in this letter agreement and the Agreement, the
terms and conditions of this letter agreement shall govern and control.

This letter agreement shall be governed by, and construed and enforced in accordance with the
laws of the State of California, without regard to conflict of laws principles.

Please acknowledge your agreement to the foregoing terms and conditions by executing this
letter agreement.

 

 

 

	 	 	 	 	 
	Very truly yours,

HENRY SCHEIN, INC.

 	 	 
	By:  	Brian S. Watson
 	 	 
	 	Name:  	Brian S. Watson 	 	 
	 	Title:  	Vice President 	 	 
	 
	ACCEPTED AND AGREED:

BIOLASE TECHNOLOGY, INC.

 	 	 
	By:  	David M. Mulder
 	 	 
	 	Name:  	David M. Mulder 	 	 
	 	Title:  	Chief Executive OfficerExhibit 10.5

Exhibit 10.5

HENRY SCHEIN, INC.

March 9, 2010

Mr. David M. Mulder

Chief Executive Officer

Biolase Technology, Inc.

4 Cromwell

Irvine, California 92618

Dear Mr. Mulder:

This letter agreement shall serve to amend that certain License and Distribution Agreement, by and
between Henry Schein, Inc. (“HSIC”) and Biolase Technology, Inc. (“Biolase”), dated as of August 8,
2006, as amended (the “Agreement”).

As of the date set forth above, the parties hereby agree as follows:

	 	1.	 	Distribution **** – All applicable U.S. and Canadian sales (as discussed
below) of Biolase products will ****:

	 	a.	 	Henry Schein Clients (being defined as customers of HSIC who are not
Non-HSIC Clients (as defined below)): HSIC will ****.

	 	b.	 	Non-HSIC Clients (being defined as ****: solely with respect to ****
sales that occur under this paragraph 1(b) (and not with respect to sales ****),
HSIC’s ****, and the mechanics of **** will be determined mutually and in good
faith by HSIC and Biolase. Biolase will ****. The same proportion of Henry
Schein Clients to Non-HSIC Clients will be used for the Canadian dental market
****. The list for both countries will be reviewed and agreed to by both parties
by March 15, 2010 and used for the entire length of the term. The processing and
shipments made by HSIC to Non-HSIC Clients will be made in the same ****;
provided that after such efforts and if, following thirty (30)
days from delivery, ****. Notwithstanding the foregoing, and only on an exception
basis, if HSIC is **** to customer who is defined ****, such sale shall be
governed by paragraph 1(a) above and treated as ****.

	 	c.	 	Notwithstanding anything contained herein to the contrary, Biolase
shall have the right for ****. It is the mutual intent of both parties that this
provision is to be invoked by Biolase ****.

	 	d.	 	**** dental products and services will continue to be exclusive to
HSIC in the U.S., Canada, and those other existing international markets where
HSIC currently has exclusivity. Subject to paragraph 1(c) above ****.

	 	 	 
	****	 	Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

 

	 	2.	 	Minimum Purchase Commitment; Non-Laser Equipment Purchases – Commencing April
15, 2010, HSIC shall make minimum world-wide actual purchase order-issued purchases (or,
at HSIC’s discretion, a prepayment) of $1.5 million per month
of Equipment (“Equipment” being defined as ****) payable one-half on the 15th and 30th of
each month for the term of this letter agreement. For the avoidance of doubt and
notwithstanding anything contained herein to the contrary, the amounts required to
purchased pursuant to this paragraph are in addition to, and may not be offset against,
HSIC obligations to the make advance payments as specifically set forth in that certain
letter agreement, dated February 16, 2010, by and between HSIC and Biolase. All other
categories of Biolase dental laser products and services (“Non-Laser Equipment”) purchased
by HSIC for the term will not be included in the minimum purchase commitment described
above.

	 	3.	 	****– HSIC will make ****for ****. The remaining ****. HSIC will make
****equal to ****. The remaining units will ****. The ****under this paragraph will be
in addition to, and exclusive of, the minimum purchase commitment, minimum equipment
purchase prepayments, and Non-Laser Equipment purchases set forth in Paragraph 2 above.
The HSIC purchase price with respect to the Waterlase MD products per this paragraph shall
be ****. The mechanics of the **** shall be further discussed by the parties’ operational
teams after the date hereof and the parties’ will develop processes for implementing the
intent of this letter agreement. HSIC agrees it shall ****, but in any event not longer
than one weeks’ time following Biolase’s sales of such units, with the specific process
****to be determined in good faith by HSIC and Biolase.

	 	4.	 	Term – one year from the date hereof; provided however, that
either HSIC or Biolase may terminate this agreement for any reason whatsoever upon 60
days’ advance written notice to the other party, and unless otherwise agreed upon in
writing, the parties will have no further purchase obligations upon such termination.
This agreement may be extended by HSIC and Biolase for an additional six (6) months upon
mutual agreement of the parties. For the avoidance of doubt, HSIC may continue to sell
its inventory of Biolase products after the expiry or termination of this agreement, and
Biolase and HSIC shall reasonably cooperate in such efforts.

	 	5.	 	Manufacturer’s Suggested Retail Price – Biolase’s MSRP for the Waterlase MD
is $****, $**** for the ezlase, and $**** for iLase.

	 	6.	 	Special Financing – Henry Schein Financial Services will continue to offer,
at its discretion, special financing to Biolase clients and pay for 100% of the cost of
doing so. Alternative financing programs are at the option of the clients and Biolase.

	 	7.	 	Additional Bundling Promotions – Such promotions will be offered from time to
time as determined by HSIC management. One example would be ****. Biolase can also
offer special programs at its own cost or as negotiated with shared cost.

	 	8.	 	Luminaries – Both parties support the idea of creating many more luminaries.
Upon mutual agreement by HSIC and Biolase, HSIC would **** for services rendered in
connection with such role. If that program is adopted, the parties will ****. Current
maximum number of new luminaries under this program is to be ****.

	 	9.	 	Inventory –HSIC will have the option to upgrade **** inventory **** at ****.
The upgrade orders will ****, but following the ****, upgrades will be ****.

	 	 	 
	****	 	Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

2

 

	 	10.	 	New Additional Cash Spiff Incentives for HSIC Sales People – For the term,
$**** will be paid on each Waterlase MD sale for sales to HSIC Clients only. This amount
will be allocated to one or more sales persons at the discretion of the HSIC Regional
Manager. For sales to HSIC Clients only, HSIC FSCs will also receive a $**** additional
spiff for each ezlase or iLase sale made in their territory. Amounts under this paragraph
10 will be 100% funded by HSIC.

	 	11.	 	New Incentives for Regional Managers – For the term, $**** will be paid on
each Waterlase MD sale to HSIC Clients only, provided each HSIC manager achieves their
defined annual target. Amounts under this paragraph 11 will be 100% funded by HSIC.

	 	12.	 	New Incentives for HSIC Zone General Managers – For the term, $**** will be
paid on each Waterlase MD sale to HSIC Clients only provided each HSIC manager achieves
**** of their Zone defined annual target. Amounts under this paragraph 12 will be 100%
funded by HSIC.

	 	13.	 	Schools – HSIC will work in partnership with Biolase to install systems into
dental schools with the goal of incorporating the effective use of lasers within the
curriculum of the school (e.g., **** ).

	 	14.	 	**** – HSIC will continue to support the “Triangle of Success” process that
HSIC and Biolase played a key role in solidifying this past year.

	 	15.	 	Outside North America – HSIC will continue to work with Biolase as a
Preferred Vendor Partner and the parties will continue the exclusive rights in various
markets as previously agreed to.

	 	16.	 	**** – HSIC will support a Biolase-initiated **** program under certain
circumstances for ****. The program may also be made available to ****. The overall goal
is to ensure these programs are ****. Biolase will do so on limited live pilot before
finalizing a full program.
	 
	 	17.	 	Biolase **** – Biolase agrees ****.

	 	18.	 	New Forecasts for Purchase Orders – HSIC agrees to provide on the 30th of
each month, a six-month rolling forecast for product category purchases expected on future
purchase orders as specified by both parties.

All amounts herein reference U.S. dollars. This letter agreement extends the term of the Agreement
and amends certain terms and conditions of the Agreement. All other terms and conditions of the
Agreement that are not modified by this letter agreement are hereby ratified and confirmed in all
respects, and shall remain in full force and effect. Should there be any conflict between the terms
and conditions contained in this letter agreement and the Agreement, the terms and conditions of
this letter agreement shall govern and control.

[SIGNATURES APPEAR ON NEXT PAGE]

	 	 	 
	****	 	Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

3

 

Please acknowledge your agreement to the foregoing terms and conditions by executing this letter
agreement.

	 	 	 	 	 
	Sincerely,

 	 
	/s/ Brian S. Watson
 	 	 	 
	Brian S. Watson 	 
	Vice President, Strategic and Business Planning

Henry Schein, Inc. 	 	 	 
	 
	ACCEPTED AND AGREED:

 	 
	/s/ David M. Mulder
 	 	 	 
	David M. Mulder 	 	 
	Chief Financial Officer

Biolase Technology, Inc. 	 	 

	 	 	 
	****	 	Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}]]